Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1468-1480. doi: 10.26355/eurrev_202002_20206.
This study aimed to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) using CalliSpheres beads loading with arsenic trioxide (ATO) (CBATO) in unresectable hepatocellular carcinoma (HCC) patients.
Eighty-six unresectable HCC patients about to receive TACE with CBATO or conventional TACE (cTACE) with ATO were consecutively enrolled and divided into CBATO group (N=38) or cTACE group (N=48), respectively. Treatment response at 3 months (M3) and 6 months (M6) after the first treatment, and the progression-free survival (PFS) and overall survival (OS) were evaluated. Also, the biochemical indexes were documented before treatment, at 7 days, M3, and M6 after the first treatment.
The 3-month complete response (CR), overall response rate (ORR), and the 6-month CR, ORR, as well as the disease control rate (DCR) were increased in CBATO group compared with the cTACE group. Also, the TACE with CBATO was an independent predicting factor for lower stable disease+ progressive disease (non-ORR). Besides, PFS and OS were longer in CBATO group compared with cTACE group. Referring to biochemical indexes (including liver function indexes, kidney function indexes, and blood routine indexes), no difference between the two groups was found. As for adverse events, the prevalence of nausea and vomiting was decreased, while the prevalence of other adverse events were similar in CBATO group compared to cTACE group.
TACE with CBATO is more effective and equally tolerant compared with cTACE in treating unresectable HCC patients.
本研究旨在探讨载三氧化二砷（ATO）的载药微球（CBATO）经导管动脉化疗栓塞（TACE）治疗不可切除肝细胞癌（HCC）患者的疗效和安全性。
连续纳入 86 例拟行 TACE 治疗的不可切除 HCC 患者，分别采用 CBATO（n=38）或载 ATO 的常规 TACE（cTACE，n=48）。评估两组患者首次治疗后 3 个月（M3）和 6 个月（M6）的治疗反应，无进展生存期（PFS）和总生存期（OS）。并记录两组患者治疗前、首次治疗后第 7 天、M3 和 M6 的生化指标。
CBATO 组的 3 个月完全缓解（CR）率、总缓解率（ORR）和 6 个月 CR 率、ORR 率以及疾病控制率（DCR）均高于 cTACE 组。此外，TACE 联合 CBATO 是降低稳定疾病+进展疾病（非 ORR）的独立预测因素。同时，CBATO 组的 PFS 和 OS 长于 cTACE 组。就生化指标（包括肝功能、肾功能和血常规指标）而言，两组间无差异。至于不良反应，CBATO 组恶心呕吐的发生率降低，而其他不良反应的发生率与 cTACE 组相似。
与 cTACE 相比，TACE 联合 CBATO 治疗不可切除 HCC 患者更有效且耐受性相当。
